FIGURE 5 from LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency

LP-184 and PARPi combination showed strong in vitro synergy. A and B, LP-184 and olaparib/rucaparib synergy in the HRD prostate cancer cell line 22RV1. Cells were treated by 5*4 combinations of LP-184 (0, 60, 120, 240, 480 nmol/L) and olaparib/rucaparib (0, 450, 1,350, 4,050 nmol/L) for 10 days. Cell viability at each combination was used as input for SynergyFinder 3.0 (29) to generate the graphs. C, Treatment of LP-184 as a single agent and in combination with olaparib in OVCAR3 cell line. OVCAR3 cells were treated by combinations of LP-184 and olaparib at various concentrations as shown for 10 days. Cell survival was normalized by the viability of untreated cells.